Company intelligence / Profile preview

Endo International plc

Malvern, Pennsylvania, United Statesendo.com ↗

Ownership: Public · NDOI
Employees: ~492
Development stage: Commercial

Overview

Endo has multiple approved products including Xiaflex (collagenase clostridium histolyticum) for Dupuytren's contracture and Peyronie's disease, which generated $475 million in sales in 2023. The company recently emerged from bankruptcy in 2024 with a reorganized structure and reduced debt.

Therapeutic areas: RheumatologyImmunologyNeurologyMen's Health
Modalities: Small moleculesenzymesmolecular gluemonoclonal antibody
Industry: Biotech

Drug pipeline

27 assets

dexfenfluramine

Approved

26 more assets in the full pipeline.

Request access →

Partnerships

Mallinckrodt Pharmaceuticals (merger announced March 2025)

Beyond the preview

Go deeper on Endo International plc.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endo International plc.

Explore the full profile